Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era

References

• Ali M, Nelson AR, Lopez AL, Sack DA. Updated Global Burden of Cholera in Endemic Countries. PLoS Negl Trop Dis 2015; 9(6):e0003832; PMID:26043000; http://dx.doi.org/10.1371/journal.pntd.0003832
   PubMed Web of Science ®Google Scholar
• Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, Kim DR, Ali M, Clemens JD. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Neglected Tropical Diseases [electronic resource] 2008; 2(2):e173; PMID:18299707
   PubMedGoogle Scholar
• Sanchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005; 17(4):388-98; PMID:15963708; http://dx.doi.org/10.1016/j.coi.2005.06.007
   PubMed Web of Science ®Google Scholar
• Jonson G, Osek J, Svennerholm AM, Holmgren J. Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development. Infect Immun 1996; 64(9):3778-85; PMID:8751929
   PubMed Web of Science ®Google Scholar
• Nelson EJ, Harris JB, Glenn Morris J, Calderwood SB, Camilli A. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat Rev Micro 2009; 7(10):693-702; http://dx.doi.org/10.1038/nrmicro2204
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11(4 Suppl):S45-53; PMID:15812489; http://dx.doi.org/10.1038/nm1213
   PubMed Web of Science ®Google Scholar
• Levine MM. Can needle-free administration of vaccines become the norm in global immunization? Nat Med 2003; 9(1):99-103; PMID:12514720; http://dx.doi.org/10.1038/nm0103-99
   PubMed Web of Science ®Google Scholar
• Harris JB, LaRocque R, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet 2012; (379):2466-76; PMID:22748592; http://dx.doi.org/10.1016/S0140-6736(12)60436-X
   PubMed Web of Science ®Google Scholar
• Roy SK, Hossain MJ, Khatun W, Chakraborty B, Chowdhury S, Begum A, Mah-e-Muneer S, Shafique S, Khanam M, Chowdhury R. Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. BMJ 2008; 336(7638):266-8; PMID:18184631; http://dx.doi.org/10.1136/bmj.39416.646250.AE
   PubMed Web of Science ®Google Scholar
• Bhandari N, Mazumder S, Taneja S, Dube B, Agarwal RC, Mahalanabis D, Fontaine O, Black RE, Bhan MK. Effectiveness of zinc supplementation plus oral rehydration salts compared with oral rehydration salts alone as a treatment for acute diarrhea in a primary care setting: a cluster randomized trial. Pediatrics 2008; 121(5):e1279-85; PMID:18450870; http://dx.doi.org/10.1542/peds.2007-1939
   PubMedGoogle Scholar
• Lukacik M, Thomas RL, Aranda JV. A meta-analysis of the effects of oral zinc in the treatment of acute and persistent diarrhea. Pediatrics 2008; 121(2):326-336; PMID:18245424; http://dx.doi.org/10.1542/peds.2007-0921
   PubMed Web of Science ®Google Scholar
• Nelson EJ, Nelson DS, Salam MA, Sack DA. Antibiotics for both moderate and severe cholera. N Engl J Med 2011; 364(1):5-7; PMID:21142691; http://dx.doi.org/10.1056/NEJMp1013771
   PubMed Web of Science ®Google Scholar
• Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ 1967; 36(6):871-83; PMID:4865453
   PubMed Web of Science ®Google Scholar
• Koo D, Traverso H, Libel M, Drasbek C, Tauxe R, Brandling-Bennett D. Epidemic cholera in Latin America, 1991–1993: implications of case definitions used for public health surveillance. Bull Pan Am Health Organ 1996; 30(2):134-43; PMID:8704754
   PubMedGoogle Scholar
• Anh DD, Lopez AL, Tran HTM, Cuong NV, Thiem VD, Ali M, Deen JL, von Seidlein L, Sack DA. Oral cholera vaccine development and use in Vietnam. PLoS medicine 2014; 11(9):e1001712; PMID:25180511; http://dx.doi.org/10.1371/journal.pmed.1001712
   PubMed Web of Science ®Google Scholar
• WHO. Revitalizing control efforts for cholera. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 2015; 90(40):530-4.
   PubMedGoogle Scholar
• Dellepiane N, Wood D. Twenty-five years of the WHO vaccines prequalification programme (1987–2012): lessons learned and future perspectives. Vaccine 2015; 33(1):52-61; PMID:24300593; http://dx.doi.org/10.1016/j.vaccine.2013.11.066
   PubMed Web of Science ®Google Scholar
• Martin S, Lopez AL, Bellos A, Deen J, Ali M, Alberti K, Anh DD, Costa A, Grais RF, Legros D. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ 2014; 92(12):881-93; PMID:25552772; http://dx.doi.org/10.2471/BLT.14.139949
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988; 158(2):372-7; PMID:3042876; http://dx.doi.org/10.1093/infdis/158.2.372
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335(8684):270-3; PMID:1967730; http://dx.doi.org/10.1016/0140-6736(90)90080-O
   PubMed Web of Science ®Google Scholar
• Lucas MES, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352(8):757-67; PMID:15728808; http://dx.doi.org/10.1056/NEJMoa043323
   PubMed Web of Science ®Google Scholar
• Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PV, Rao MR. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997; 349(9047):231-5; PMID:9014909; http://dx.doi.org/10.1016/S0140-6736(96)06107-7
   PubMed Web of Science ®Google Scholar
• WHO. Cholera vaccines: WHO position paper. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 2010; 85(13):117-28.
   PubMedGoogle Scholar
• WHO. Technical Note: Evidence of the risks and benefits of vaccinating pregnant women with WHO pre-qualified cholera vaccines during mass vaccination campaigns. 2016; http://www.who.int/cholera/vaccines/Risk_Benefits_vaccinating_pregnant_women_Technical_Note_13Jan2016.pdf?ua=1. Accessed March 20, 2016, 2016.
   Google Scholar
• Ciglenecki I, Bichet M, Tena J, Mondesir E, Bastard M, Tran NT, Antierens A, Staderini N. Cholera in pregnancy: outcomes from a specialized cholera treatment unit for pregnant women in Leogane, Haiti. PLoS Negl Trop Dis 2013 Aug 15; 7(8):e2368; http://dx.doi.org/10.1371/journal.pntd.0002368
   Google Scholar
• Khan AI, Chowdhury F, Leung DT, Larocque RC, Harris JB, Ryan ET, Calderwood SB, Qadri F. Cholera in pregnancy: Clinical and immunological aspects. Int J Infect Dis 2015; 39:20-4; PMID:26283553; http://dx.doi.org/10.1016/j.ijid.2015.08.006
   PubMed Web of Science ®Google Scholar
• Anh D, Canh D, Lopez A, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007; 25(6):1149-55; PMID:17055622; http://dx.doi.org/10.1016/j.vaccine.2006.09.049
   PubMed Web of Science ®Google Scholar
• Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE 2008; 3(6):e2323; PMID:18523643; http://dx.doi.org/10.1371/journal.pone.0002323
   PubMed Web of Science ®Google Scholar
• Desai SN, Akalu Z, Teshome S, Teferi M, Yamuah L, Kim DR, Yang JS, Hussein J, Park JY, Jang MS, et al. A randomized, placebo-controlled trial evaluating safety and immunogenicity of the killed, bivalent, whole-cell oral cholera vaccine in Ethiopia. Am J Trop Med Hyg 2016; 21(2):194–201; PMID:26681205
   Web of Science ®Google Scholar
• Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, et al. Five year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013; 13(12):1050-6; PMID:24140390; http://dx.doi.org/10.1016/S1473-3099(13)70273-1
   PubMed Web of Science ®Google Scholar
• Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Asaduzzaman M, Akter A, Khan A, et al. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med 2016; 374(18):1723-1732; PMID:27144848; http://dx.doi.org/10.1056/NEJMoa1510330
   PubMed Web of Science ®Google Scholar
• Qadri F, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Begum YA, Bhuiyan TR, Chowdhury MI, Uddin MJ, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 2015; 386(10001):1362-71; PMID:26164097; http://dx.doi.org/10.1016/S0140-6736(15)61140-0
   PubMed Web of Science ®Google Scholar
• Kanungo S, Paisley A, Lopez A, Bhattacharya M, Manna B, Kim DR, Han SH, Attridge S, Carbis R, Rao R, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009; 27(49):6887-93; PMID:19761838; http://dx.doi.org/10.1016/j.vaccine.2009.09.008
   PubMed Web of Science ®Google Scholar
• Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, Franke MF, Saha A, Yu Y, Kováč P, Calderwood SB, et al. Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti. PLoS Negl Trop Dis 2014; 8(5):e2828; PMID:24786645; http://dx.doi.org/10.1371/journal.pntd.0002828
   PubMedGoogle Scholar
• Desai SN, Akalu Z, Teferi M, Manna B, Teshome S, Park JY, Yang JS, Kim DR, Kanungo S, Digilio L. Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings. Trop Med Int Health 2016; 21(2):194-201; http://dx.doi.org/10.1111/tmi.12641
   PubMed Web of Science ®Google Scholar
• Ivers LC, Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, Rychert J, LaRocque RC, Xu P, Kovácˇ P, et al. Immunogenicity of the bivalent oral cholera vaccine Shanchol in Haitian adults with HIV infection. J Infect Dis 2015; 212(5):779–83; PMID:25722294
   PubMed Web of Science ®Google Scholar
• Baik YO, Choi SK, Olveda RM, Espos RA, Ligsay AD, Montellano MB, Yeam JS, Yang JS, Park JY, Kim DR, et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine 2015; 33(46):6360-5; PMID:26348402; http://dx.doi.org/10.1016/j.vaccine.2015.08.075
   PubMed Web of Science ®Google Scholar
• Lebens M, Karlsson SL, Kallgard S, Blomquist M, Ekman A, Nygren E, Holmgren J. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens. Vaccine 2011; 29(43):7505-13; PMID:21807059; http://dx.doi.org/10.1016/j.vaccine.2011.06.121
   PubMed Web of Science ®Google Scholar
• Larena M, Holmgren J, Lebens M, Terrinoni M, Lundgren A. Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signaling. Journal of immunology (Baltimore, Md. : 1950) 2015; 194(8):3829-39; PMID:25786687; http://dx.doi.org/10.4049/jimmunol.1401633
   PubMed Web of Science ®Google Scholar
• Saha A, Khan A, Salma U, Jahan N, Bhuiyan TR, Chowdhury F, Khan AI, Khanam F, Muruganandham S, Reddy Kandukuri S, et al. The oral cholera vaccine Shanchol when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. Vaccine 2016; 34(13):1551-8; PMID:26896684; http://dx.doi.org/10.1016/j.vaccine.2016.02.020
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366(9479):44-49; PMID:15993232; http://dx.doi.org/10.1016/S0140-6736(05)66550-6
   PubMed Web of Science ®Google Scholar
• Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, et al. Herd Protection by a Bivalent Killed Whole-Cell Oral Cholera Vaccine in the Slums of Kolkata, India. Clin Infect Dis 2013; 56(8):1123-31; PMID:23362293; http://dx.doi.org/10.1093/cid/cit009
   PubMed Web of Science ®Google Scholar
• Binagwaho A, Nyatanyi T, Nutt CT, Wagner CM. Disease outbreaks: support for a cholera vaccine stockpile. Nature 2012; 487(7405):39; PMID:22763542; http://dx.doi.org/10.1038/487039c
   PubMed Web of Science ®Google Scholar
• Pape JW, Rouzier V. Embracing oral cholera vaccine–shifting response to cholera. N Engl J Med 2014; 370(22):2067-9; PMID:24869720; http://dx.doi.org/10.1056/NEJMp1402837
   PubMed Web of Science ®Google Scholar
• Severe K, Rouzier V, Anglade SB, Bertil C, Joseph P, Deroncelay A, Mabou MM, Wright PF, Guillaume FD, Pape JW. Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up. Am J Trop Med Hyg 2016; 94(5):1136-42; PMID:26928838; http://dx.doi.org/10.4269/ajtmh.15-0700
   PubMedGoogle Scholar
• Nogareda F. Oral cholera vaccine campaigns 2013–2015: monitoring andevaluation. World Health Organization OCV Monitoring and Evaluation Working Group Meeting. Paper presented at: World Health Organization OCV Monitoring and Evaluation Working Group Meeting2015; Geneva.
   Google Scholar
• Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Diallo AA, Itama C, Page AL, Quilici ML, et al. Use of Vibrio cholerae Vaccine in an Outbreak in Guinea. N Engl J Med 2014; 370(22):2111-20; PMID:24869721; http://dx.doi.org/10.1056/NEJMoa1312680
   PubMed Web of Science ®Google Scholar
• Ivers LC, Hilaire IJ, Teng JE, Almazor CP, Jerome JG, Ternier R, Boncy J, Buteau J, Murray MB, Harris JB, et al. Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. The Lancet Global Health 2015; 3(3):e162-e168; PMID:25701994; http://dx.doi.org/10.1016/S2214-109X(14)70368-7
   PubMed Web of Science ®Google Scholar
• Abubakar A, Azman AS, Rumunu J, Ciglenecki I, Helderman T, West H, Lessler J, Sack DA, Martin S, Perea W, et al. The First Use of the Global Oral Cholera Vaccine Emergency Stockpile: Lessons from South Sudan. PLoS Med 2015; 12(11):e1001901; PMID:26576044; http://dx.doi.org/10.1371/journal.pmed.1001901
   PubMed Web of Science ®Google Scholar
• Desai SN, Pezzoli L, Martin S, Costa A, Rodriguez C, Legros D, Perea W. A second affordable oral cholera vaccine: implications for the global vaccine stockpile. The Lancet. Global health 2016; 4(4):e223-224; PMID:27013303
   PubMedGoogle Scholar
• WHO. Diarrhoeal disease fact sheet 2013. 2016.
   Google Scholar
• Pasetti M, Simon J, Sztein M, Levine M. Immunology of gut mucosal vaccines. Immunol Rev 2011; 239(1):125-148; PMID:21198669; http://dx.doi.org/10.1111/j.1600-065X.2010.00970.x
   PubMed Web of Science ®Google Scholar
• Qadri F, Bhuiyan TR, Sack DA, Svennerholm AM. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 2013; 31(3):452-60; PMID:23153448; http://dx.doi.org/10.1016/j.vaccine.2012.11.012
   PubMed Web of Science ®Google Scholar
• Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 2010; 8(129); PMID:20920375
   PubMed Web of Science ®Google Scholar
• Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 2011; 29(46):8285-8292; PMID:21907255; http://dx.doi.org/10.1016/j.vaccine.2011.08.108
   PubMed Web of Science ®Google Scholar
• Kanungo S, Desai SN, Nandy RK, Bhattacharya MK, Kim DR, Sinha A, Mahapatra T, Yang JS, Lopez AL, Manna B, et al. Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. PLoS Negl Trop Dis 2015; 9(3):e0003574; PMID:25764513; http://dx.doi.org/10.1371/journal.pntd.0003574
   PubMed Web of Science ®Google Scholar
• WHO. Outbreak news. Oral cholera vaccine campaign among internally displaced persons in South Sudan. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations 2014; 89(20):205-6.
   PubMedGoogle Scholar
• Desai SN, Cravioto A, Sur D, Kanungo S. Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines. Hum Vaccin Immunother 2014; 10(6):1457-65; PMID:24861554; http://dx.doi.org/10.4161/hv.29199
   PubMed Web of Science ®Google Scholar
• Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, et al. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis 2016; 62(11):1329-35; PMID:27001804; http://dx.doi.org/10.1093/cid/ciw145
   PubMed Web of Science ®Google Scholar